Allergy Therapeutics seeks approval to issue new shares ahead of possible fundraising

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) plans to ask shareholders on 29 December for permission to issue up to 610 million new shares, roughly 10% of its current share count, as it considers a potential equity raise. The company says any fundraising would take place through private placements without pre-emption rights, allowing shares to be sold quickly to new or existing investors. The move is tied to its planned dual listing in Hong Kong in the first half of 2026.